it is under review at the European Medicines Agency and slated to start a Phase III trial in the U.S...Galecto Biotech AB, of Lund, Sweden, added two additional investors, Sunstone Capital and SEED Capital to its first round financing to advance a series of small-molecule inhibitors of Galectin-3 for treating idiopathic pulmonary fibrosis and other conditions...In other news, Novartis said the FDA approved mTOR inhibitor Afinitor (everolimus) for non-cancerous kidney tumors associated with tuberous

In other news, Biostar, via its Xhaanxi Winan subsidiary, has been selected to exclusively supply Huanghangning tablets, for cardiovascular disease, to all hospitals in Liaoning, Hebei, and Shandong for up to three years...In other news, Boehringer launched a worldwide registry to study treatment regimes for stroke prevention in nonvalvular atrial fibrillation and respective patient outcomes...In other news, Janssen launched a division, Janssen Therapeutics EMEA, dedicated to bringing investigational

In other news, the CHMP also confirmed a positive benefit-risk profile for Novartis' once-daily oral Gilenya (fingolimod), while agreeing to a labeling update for the multiple sclerosis (MS) drug

In other news, AMT reported that shareholders have approved all the resolutions proposed for a corporate restructuring and financing transaction, which will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV...Astellas Pharma Inc., of Tokyo, and Vical Inc., of San Diego, finalized the design for a pivotal Phase III trial of TransVax cytomegalovirus vaccine for transplant recipients, triggering a $10 million milestone payment to Vical

Sunesis Pharmaceuticals Inc., of San Francisco, said Royalty Pharma agreed to pay the company $25 million, under certain circumstances related to the successful development of lead candidate vosaroxin, to acquire a royalty on future worldwide sales of the acute myeloid leukemia drug...Under the terms, Royalty Pharma agreed to invest the $25 million immediately following that interim analysis if either the study stops for efficacy or the trial's one-time sample size increase is being implemented...If

Under the terms, Flamel issued a $12 million senior note to Eclat Holdings LLC and agreed to pay Eclat Holdings an earnout payment of 20 percent of the gross profit generated by the Eclat launch products...In other news, Medivir said it will file an application in Europe to start Phase I trials of MIV-711, a cathepsin K inhibitor aimed at treating bone disorders such as osteoporosis, osteoarthritis or bone metastases

Under the terms, Flamel issued a $12 million senior note to Eclat Holdings LLC and agreed to pay Eclat Holdings an earnout payment of 20 percent of the gross profit generated by the Eclat launch products...Plethora Solutions Holdings plc, of London, said it held a pre-submission meeting with the Rapporteur and Co-Rapporteur (Spain and the UK, respectively) for its PSD502 treatment for premature ejaculation and is on track to file the dossier with the European Medicines Agency in the first half of

to return to full dosing and new patients in the U.S...Tekmira secured rights to develop the drug, TKM-ALDH2, through an exclusive license from Cambridge, Mass.-based Alnylam Pharmaceuticals Inc

Last year, it put all other R&D programs on hold and cut 72 of 82 employees to conserve cash...EUSA Pharma Inc., of Oxford, UK, acquired the exclusive worldwide development and commercialization rights to Asparec in acute lymphoblastic leukemia (ALL) from Alizé Pharma SAS, of Lyon, France

The National Institutes of Health (NIH) is accepting comments for 30 days on its proposal to grant an exclusive worldwide license to Kite Pharma Inc., of Los Angeles, for patents covering T cells engineered to express MAGE-A3, MAGE-A12 or SSX-2 T-cell receptors or EGFRvIII chimeric antigens, as well as methods of using the T cells to treat or prevent various types of cancer

Amarantus also has an option to purchase all of the Parkinson's disease IP for $500,000 in common stock and maintains a right of first refusal to acquire the balance of the NuroPro platform for Alzheimer's disease, amyotrophic lateral sclerosis and other neurodegenerative diseases...The '112 study is the first of two pivotal trials designed to support the filing of a new drug application with the FDA and a marketing authorization application with the European Medicines Agency

Innate Pharma SA, of Marseilles, France, said its scientific co-founder Eric Vivier, a professor at the Center of Immunology of Marseille-Luminy, published preclinical data in Science showing mice that do not express the NK activating receptor NKp46 have an enhanced resistance to some viral infections...Innate Pharma and INSERM, the French National Institute of Health and Medical Research, have filed patent applications relating to that discovery...Inc., of Whitehouse Station, N.J., said the European

Aptalis Pharma Inc., of Bridgewater, N.J., and Gilead Sciences Inc., of Foster City, Calif., said the FDA approved the new drug application for Viread (tenofovir disoproxil fumarate) oral powder in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2 to 5...NovaDel Pharma Inc., of Bridgewater, N.J., said it will not have adequate cash to meet working capital needs after the end of January and continues to explore strategic alternatives

Pherecydes Pharma SA, of Paris, said it received €900,000 (US$1.2 million) from France's General Directorate for Armaments to partly finance the PACOBURNS project, which is set up to explore the possibility of using bacteriophages to combat bacterial infections that are resistant to antibiotics, especially skin infections

NovAliX SAS, of Strasbourg, France, is partnering with Teijin Pharma Ltd., of Tokyo, to develop drug candidates against multiple targets across different therapeutic areas...to explore the feasibility of a controlled-release formulation of a compound for delivery to the joints

DFH Pharma Inc., of Gaithersburg, Md., is collaborating with the National Cancer Institute (NCI) to develop the next generation of HIV maturation inhibitor drugs...The goal is to initiate clinical trials with one or more molecules in the near future

The company said it plans to organize an end-of-Phase II meeting with the FDA by the end of the first quarter to move the li-Key hybrid-based HER2/neu peptide vaccine into a pivotal program in women with loco-regional breast cancer that express low to moderate levels of HER2...Regeneron received a nonexclusive license to certain patents relating to VEGF receptor programs...Zealand Pharma A/S, of Copenhagen, Denmark, received €3 million (US$3.917 million) in milestone payments under a potential €€140

In other news, AstraZeneca and Hutchison MediPharma Ltd. (HMP), of London, entered a global licensing, co-development and commercialization agreement for Volitinib (HMPL-504), a highly selective inhibitor of the c-Met receptor tyrosine kinase to treat of cancer, currently in preclinical studies...Covis Pharma Sarl, of Zug, Switzerland, agreed with GlaxoSmithKline plc, of London, to acquire commercial rights to Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine

Covis Pharma Sarl, of Zug, Switzerland, agreed with GlaxoSmithKline plc, of London, to acquire commercial rights to Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate) and Zantac injection (ranitidine hydrochloride) in the U.S...Roche AG, of Basel, Switzerland, submitted a marketing authorization application to the European Medicines Agency for vismodegib, triggering a $6 million milestone payment to its partner Curis Inc., of Lexington, Mass